Difference between revisions of "Mitomycin (Mutamycin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
Warner-admin (talk | contribs) m (Text replacement - " - obsolete" to "_-_historical") |
||
Line 16: | Line 16: | ||
==Diseases for which is was used== | ==Diseases for which is was used== | ||
− | *[[Non-small cell lung | + | *[[Non-small cell lung cancer_-_historical|Non-small cell lung cancer]] |
==Patient drug information== | ==Patient drug information== |
Revision as of 17:03, 29 January 2018
General information
Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Anal cancer
- Bladder cancer
- Cervical cancer
- Cholangiocarcinoma
- Esophageal cancer
- Head and neck cancer
- Mesothelioma
Diseases for which is was used
Patient drug information
- Mitomycin (Mutamycin) patient drug information (Chemocare)[3]
- Mitomycin (Mutamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/24/1981: Initial FDA approval
Also known as
- Generic names: mitomycin-C, MTC
- Brand names: Lyomit, Mitocin, Mitocyte, Mitosol, Mitozytrex, Mutamycin